News
IXHL
3.150
-5.12%
-0.170
Weekly Report: what happened at IXHL last week (0914-0918)?
Weekly Report · 09/21 10:12
Weekly Report: what happened at IXHL last week (0907-0911)?
Weekly Report · 09/14 10:16
Incannex doses first patient in DReAMzz study
TipRanks · 09/09 12:25
Incannex Begins Phase 2 DReAMzz Sleep Apnea Study
TipRanks · 09/09 12:00
Weekly Report: what happened at IXHL last week (0831-0904)?
Weekly Report · 09/07 10:10
Weekly Report: what happened at IXHL last week (0824-0828)?
Weekly Report · 08/31 10:17
Psychedelic: SciSparc, Clearmind publish patent application for PTSD treatment
TipRanks · 08/27 16:10
Incannex doses first patient in DReAMzz study of IHL-42X
TipRanks · 08/25 12:56
Incannex Begins Phase 2 DReAMzz Trial for IHL-42X
TipRanks · 08/25 11:55
Weekly Report: what happened at IXHL last week (0817-0821)?
Weekly Report · 08/24 10:18
Weekly Report: what happened at IXHL last week (0810-0814)?
Weekly Report · 08/17 10:19
Incannex receives additional A$5.1M R&D tax incentive refund
TipRanks · 08/11 13:25
Incannex Healthcare Receives Final A$5.1M R&D Tax Incentive Refund Following Approval Of Its Overseas Findings And Amendment Of Its FY25 Tax Return
Benzinga · 08/11 12:09
Incannex Secures A$5.1M R&D Tax Incentive Refund
TipRanks · 08/11 12:01
Weekly Report: what happened at IXHL last week (0803-0807)?
Weekly Report · 08/10 10:14
Weekly Report: what happened at IXHL last week (0727-0731)?
Weekly Report · 08/03 10:13
Weekly Report: what happened at IXHL last week (0720-0724)?
Weekly Report · 07/27 10:17
Incannex commences screening in DReAMzz trial
TipRanks · 07/23 12:10
Incannex Healthcare Begins Participant Screening In Its DReAMzz Phase 2 Dose Confirmation Study Evaluating IHL-42X To Treat Obstructive Sleep Apnea
Benzinga · 07/23 12:04
Incannex Begins Phase 2 DReAMzz Screening for IHL-42X
TipRanks · 07/23 11:59
More
Webull provides a variety of real-time IXHL stock news. You can receive the latest news about Incannex Healthcare Ltd through multiple platforms. This information may help you make smarter investment decisions.
About IXHL
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing combination medicines that target the underlying biological pathways associated with chronic conditions, including obstructive sleep apnoea, rheumatoid arthritis, and generalized anxiety disorder. Its lead clinical program, IHL-42X, is an oral fixed-dose combination of dronabinol and acetazolamide designed to target underlying mechanisms and act synergistically in the treatment of obstructive sleep apnoea. IHL-42X has completed a Phase II clinical trial. PSX-001 is a synthetic psilocybin treatment for the treatment of generalized anxiety disorder. PSX-001 has completed a Phase II clinical trial. IHL-675A is an oral fixed-dose combination of cannabidiol and hydroxychloroquine sulfate designed to act synergistically to alleviate inflammatory conditions, such as rheumatoid arthritis. IHL-675A is in a Phase II clinical development program.